PMID- 19299439
OWN - NLM
STAT- MEDLINE
DCOM- 20090724
LR  - 20151119
IS  - 1352-4585 (Print)
IS  - 1352-4585 (Linking)
VI  - 15
IP  - 5
DP  - 2009 May
TI  - The clinical effect of neutralizing antibodies against interferon-beta is 
      independent of the type of interferon-beta used for patients with 
      relapsing-remitting multiple sclerosis.
PG  - 601-5
LID - 10.1177/1352458508101946 [doi]
AB  - OBJECTIVE: To establish whether the clinical effect of neutralizing antibodies 
      (NAbs) against interferon-beta (IFN beta) depends on the type of IFNbeta (1a or 
      1b) used for treatment of patients with relapsing-remitting multiple sclerosis 
      (MS). INTRODUCTION: NAbs against IFN beta-1b appear faster and may be more evenly 
      distributed on IgG subclasses, whereas NAbs against IFN beta-1a develop more 
      slowly and may be devoid of IgG3. This might cause different clinical responses 
      to NAbs. DESIGN/PATIENTS: All Danish MS-patients who had started first-time 
      treatment with IFNbeta-1a 22 microg s.c tiw (Rebif22) or IFN beta-1b 250 microg 
      s.c. qod (Betaferon) before January 1st 2003 were included. Relapses were 
      recorded at bi-annual visit. METHODS: We measured NAbs every 12 months using a 
      clinically validated cytopathic effect assay. A blood sample with a neutralizing 
      capacity of 20% or more was considered as NAb-positive. We used a mixed logistic 
      regression analysis in which NAb-status (three levels), IFN beta-preparation, and 
      time since treatment started were included as explanatory variables, and relapse 
      rate as response variable. RESULTS: In 1,309 patients, who were observed for 
      21,958 months, 32.3% were classified as NAb-positive. The odds-ratio (OR) for 
      relapses in NAb-positive months compared with NAb-negative months was 1.25; P = 
      0.02. The risk of relapses was higher with Betaferon than with Rebif22 (OR 1.26; 
      P < 0.01). The effect of NAb-level on relapses was independent of whether the 
      patients were treated with Betaferon or Rebif22 (P = 0.89) and of time (P = 
      0.80). CONCLUSION: NAbs caused by IFNbeta-1a s.c. do not differ from NAbs caused 
      by IFNbeta-1b in their detrimental clinical effect.
FAU - Koch-Henriksen, N
AU  - Koch-Henriksen N
AD  - Department of Neurology, Aarhus University Hospital in Aalborg, Denmark and The 
      Danish MS Treatment Register, Copenhagen University Hospital Rigshospitalet, 
      Copenhagen, Denmark. koch-henriksen@stofanet.dk
FAU - Sorensen, P S
AU  - Sorensen PS
FAU - Bendtzen, K
AU  - Bendtzen K
FAU - Flachs, E M
AU  - Flachs EM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090319
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Immunoglobulin G)
RN  - 145155-23-3 (Interferon beta-1b)
RN  - 77238-31-4 (Interferon-beta)
RN  - XRO4566Q4R (Interferon beta-1a)
SB  - IM
MH  - Adjuvants, Immunologic/*therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibody Specificity
MH  - Drug Resistance/immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Interferon beta-1a
MH  - Interferon beta-1b
MH  - Interferon-beta/*immunology/*therapeutic use
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Relapsing-Remitting/*drug therapy/*immunology
MH  - Registries
MH  - Secondary Prevention
MH  - Young Adult
EDAT- 2009/03/21 09:00
MHDA- 2009/07/25 09:00
CRDT- 2009/03/21 09:00
PHST- 2009/03/21 09:00 [entrez]
PHST- 2009/03/21 09:00 [pubmed]
PHST- 2009/07/25 09:00 [medline]
AID - 1352458508101946 [pii]
AID - 10.1177/1352458508101946 [doi]
PST - ppublish
SO  - Mult Scler. 2009 May;15(5):601-5. doi: 10.1177/1352458508101946. Epub 2009 Mar 
      19.